Navamedic ASA (OSL:NAVA)

Market Cap	385.05M
Revenue (ttm)	531.44M
Net Income (ttm)	1.29M
Shares Out	17.66M
EPS (ttm)	n/a
PE Ratio	298.49
Forward PE	30.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,666
Average Volume	11,490
Open	21.80
Previous Close	21.90
Day's Range	21.50 - 21.80
52-Week Range	19.55 - 37.30
Beta	0.49
RSI	51.31
Earnings Date	Apr 30, 2025

About Navamedic ASA

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company’s product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propioni...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2002
• Employees: 45
• Stock Exchange: Oslo Børs
• Ticker Symbol: NAVA

Financial Performance

In 2024, Navamedic ASA's revenue was 531.44 million, an increase of 3.80% compared to the previous year's 512.00 million. Earnings were 1.29 million, a decrease of -60.96%.